ascopubs.org3d
Avelumab first-line (1L) maintenance therapy in advanced urothelial carcinoma: Final analysis from a real-world study in the UK.
Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants. This is an ASCO Meeting Abstract from the 2025 ASCO ...
ascopubs.org6d
Urinary Catecholamines Predict Relapse During Complete Remission in High-Risk Neuroblastoma
Tailored Approaches in the Treatment of Patients With Colorectal Cancer Harboring Tropomyosin Receptor Kinase Fusion and Microsatellite Instability-High: A Case Report and Literature Review These ...
ascopubs.org6d
Considerations in Neoadjuvant Therapy Implementation in T3 and T4 Colon Cancer
Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma: Immune-Förster Resonance Energy Transfer and the Dynamic Tumor Immune Microenvironment Neoadjuvant ...
ascopubs.org6d
Genomic and Immune Landscape of Non–Small Cell Lung Cancer Brain Metastases
Association of Germline Pathogenic Variants in MUTYH and Other DNA Damage Response Genes With Lung Cancer Risk Among Non-Hispanic Whites and African Americans The ideas and opinions expressed in this ...
ascopubs.org6d
Scoping Review of the Impact of Culture on the Effectiveness of Quality Improvement Programs
Evolution and Recent Radiation Therapy Advancement in Uganda: A Precedent on How to Increase Access to Quality Radiotherapy Services in Low- and Middle-Income Countries Cultural differences and their ...
ascopubs.org7d
Socioeconomic Burden of Ovarian Cancer in 11 Countries
Survival and Its Predictors Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma in Ethiopia: A 6-Year Follow-Up Study Ovarian cancer remains among the most aggressive ...
ascopubs.org7d
Health Information Disparities Among Asian American People With Cancer
L.C.D ad E.C.D. are funded in part through the National Cancer Institute (P30 CA008748). E.C.D. is funded in part through the Prostate Cancer Foundation Young Investigator Award. The following ...
ascopubs.org7d
Erratum: Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights
How Should We Manage the Impact of Antimicrobial Resistance in Patients With Cancer? An Oncological and Infectious Disease Specialist Point of View Real-World Patient-Reported Outcome Measure ...
ascopubs.org7d
Erratum: Development and Implementation of a Geriatric Oncology Interdisciplinary Case–Based Educational Intervention for Cancer Care Providers
Evolution and Recent Radiation Therapy Advancement in Uganda: A Precedent on How to Increase Access to Quality Radiotherapy Services in Low- and Middle-Income Countries ...
ascopubs.org7d
Radiomics and Deep Learning Prediction of Immunotherapy-Induced Pneumonitis From Computed Tomography
Developing and Validating an Automatic Support System for Tumor Coding in Pathology Reports in Spanish Primary barriers to application of immune checkpoint inhibitor (ICI) therapy for cancer include ...
ascopubs.org7d
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
ascopubs.org9d
Real-world comparison of cabazitaxel vs. 177-lutetium-PSMA radioligand therapy in metastatic castration resistant prostate cancer.
Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients. Cancer-control outcomes of metastatic castration ...